Drug Profile
LML 134
Alternative Names: LML134Latest Information Update: 05 Oct 2021
Price :
$50
*
At a glance
- Originator Novartis
- Class Cyclobutanes; Esters; Piperazines; Piperidines; Pyridazines; Sleep disorder therapies
- Mechanism of Action Histamine H3 receptor inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Circadian rhythm sleep disorders; Sleep disorders
Most Recent Events
- 15 Feb 2019 Novartis terminates a phase II trial in Circadian rhythm sleep disorders in USA due to business reasons (NCT03141086)
- 28 Mar 2018 No recent reports of development identified for phase-I development in Sleep-disorders(In volunteers) in Germany (PO)
- 28 Jul 2017 Phase-II clinical trials in Circadian rhythm sleep disorders in USA (unspecified route) (NCT03141086)